Charles Schwab’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.72M | Buy |
442,202
+25,545
| +6% | +$446K | ﹤0.01% | 2138 |
|
|
2025
Q1 | $5.24M | Sell |
416,657
-10,820
| -3% | -$136K | ﹤0.01% | 2254 |
|
|
2024
Q4 | $4.51M | Buy |
427,477
+3,530
| +0.8% | +$37.2K | ﹤0.01% | 2373 |
|
|
2024
Q3 | $6.15M | Buy |
423,947
+8,417
| +2% | +$122K | ﹤0.01% | 2269 |
|
|
2024
Q2 | $3.54M | Buy |
415,530
+70,235
| +20% | +$598K | ﹤0.01% | 2511 |
|
|
2024
Q1 | $3.53M | Buy |
345,295
+15,745
| +5% | +$161K | ﹤0.01% | 2415 |
|
|
2023
Q4 | $1.81M | Buy |
329,550
+5,147
| +2% | +$28.2K | ﹤0.01% | 2650 |
|
|
2023
Q3 | $1.23M | Buy |
324,403
+252,792
| +353% | +$956K | ﹤0.01% | 2735 |
|
|
2023
Q2 | $480K | Buy |
71,611
+55,441
| +343% | +$371K | ﹤0.01% | 3074 |
|
|
2023
Q1 | $105K | Hold |
16,170
| – | – | ﹤0.01% | 3241 |
|
|
2022
Q4 | $138K | Buy |
+16,170
| New | +$138K | ﹤0.01% | 3229 |
|
|
2022
Q3 | – | Sell |
-106,414
| Closed | -$452K | – | 3546 |
|
|
2022
Q2 | $452K | Sell |
106,414
-40,961
| -28% | -$174K | ﹤0.01% | 3109 |
|
|
2022
Q1 | $518K | Sell |
147,375
-1,568
| -1% | -$5.51K | ﹤0.01% | 3091 |
|
|
2021
Q4 | $992K | Buy |
148,943
+9,838
| +7% | +$65.5K | ﹤0.01% | 2913 |
|
|
2021
Q3 | $1.39M | Buy |
139,105
+53,301
| +62% | +$532K | ﹤0.01% | 2773 |
|
|
2021
Q2 | $2.65M | Buy |
85,804
+1,391
| +2% | +$43K | ﹤0.01% | 2617 |
|
|
2021
Q1 | $3.68M | Buy |
+84,413
| New | +$3.68M | ﹤0.01% | 2441 |
|